AGP Executive Report
Last update: 9 hours agoDrug Regulation & Access: The European Commission has granted centralized marketing authorization for CinnaGen’s teriparatide biosimilar Zandoriah® for adult osteoporosis, with coverage including Liechtenstein (alongside EU27 plus Iceland and Norway), signaling a new step for broader availability. Rare Disease Update: Neuren Pharmaceuticals’ Rett syndrome therapy Daybu (trofinetide) received a positive CHMP opinion in Europe after re-examination, moving to a final European Commission decision; if approved, it would be the first EU-authorized treatment for neurobehavioral symptoms in eligible patients. Cross-Border Care Explained: A practical guide breaks down how cross-border healthcare works across Europe—who can use it, what costs are covered, when prior authorization applies, and how to claim—highlighting that legal and administrative rules can matter as much as the medical need. Public Health & Climate Risk: A look back at the 2003 European heatwave revisits why air conditioning remains uncommon, despite rising heat risks and the vulnerability of hospitals, schools, the elderly, children, and outdoor workers. Local Mobility for Health: Guidance notes that people with a UK Blue Badge may be able to use it abroad in some countries, including Liechtenstein, Norway and Switzerland, to ease parking access for disabilities.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
